SUBMIT ABSTRACT, EXTENDED DEADLINE 2023-10-27
Kindly note that abstracts that do not fulfill the guidelines listed below will not be reviewed by the Scientific Committee. 

ABSTRACT RULES AND REGULATIONS 

• The submitter certifies to be an investigator with a substantial involvement in the study presented in the abstract (as defined by the Vancouver recommendations) and having the right to submit and present the study.
• The submitter accepts responsibility for the accuracy and scientific content of the submitted abstract (please proofread the abstract carefully prior to submission!)
• The submitter accepts to be the contact person for all correspondence about the abstract and to inform co-authors about its status.
• The submitter confirms that all co-authors are aware of and agree to the content of the abstract and support the data presented. Furthermore, the submitter will be responsible for obtaining, and, upon request, providing proof that all authors have given permission for the submission of the abstract and agree on its content.
• Abstracts must be submitted and presented in English.
• The submitter confirms that the submitted abstract is an original paper.
• Abstracts presented previously (within the last 12 months) at national or international meetings may be submitted providing this is declared, but we particularly welcome work not previously presented at international meetings
• Abstracts will not be considered for presentation if they have been published as a full article or paper or if they have been accepted for publication (including manuscripts) in printed or electronic formats upon the submission deadline.
• The submitter confirms that the abstract has not been already submitted for the conference by a co-author.
• Statements such as “data will be present instead of providing the actual data within the abstracts are likely to lead to rejection of the abstract.
• Any financial interest in products or processes described in the abstract needs to be identified. The submitter is requested to tick the “Conflict of interest” box when submitting the abstract and to provide disclosure of interests and relationships through the abstract submission programme for each author. This includes stock ownership, membership on an advisory board or board of directors, corporate-sponsored research, or other substantive relationships.
• When selected for presentation, the author gives the IBD Nordic Conference permission for the abstract to be published on the conference website.
• Submission of an abstract constitutes a formal commitment by the author to present the abstract in the session and at the time decided upon by the IBD Nordic Organising Committee. 
• The presenting author gets to attend the full conference for free.
• The submitter confirms that copyright permissions for all third-party material (including without limitation textual extracts or illustrations, photographs, maps, diagrams and tables) have been obtained.
• Abstracts will be reviewed by a panel of experts and may be selected for oral or poster presentation (or may be rejected). Novelty is valued, and IBD Nordic prioritizes early-stage researchers. The time allotted for each oral presentation will depend on the session to which the abstract is allocated.

ABSTRACT FORMAT

• Title: should be brief and in lower case except for acronyms, names, first letter and after colons. Please do not use commercial names, non-standard abbreviations or author names in the title.
• Authors’ list: Please do not mention academic degrees.
• Structure: Abstracts should be structured in the following four sections:
  • Background: indicates the purpose of the study
  • Methods: describe pertinent experimental procedures
  • Results: summarise the results of the research
  • Conclusion: states the main conclusions
• Maximum length of 3,600 characters (excl. title & author block, INCLUDING spaces). 
• Content:
  • Please use English (UK) spelling.
  • Abbreviations may be used if standard or if spelled out and defined at the first use (put in parentheses immediately after the first mention of a term or phrase). Compounds should be mentioned with the generic name, in lower cases.
• Abstracts may include graphics and pictures (max. 4 per abstract).
• The max. size of an image is 1,5 MB and 800×800 pixels.
• Tables should be added as an image. Make sure to include the footnotes to the table within this image.